DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the INDO US BIOTECH LTD (INDOUS) share price today?

INDO US BIOTECH LTD (INDOUS) is trading at ₹87.28 on the NSE, up 1.84% on the day. Source: DocStoX.

What is the PE ratio of INDO US BIOTECH LTD?

INDO US BIOTECH LTD has a price-to-earnings (PE) ratio of 10.8 in the FMCG sector.

What is the market capitalisation of INDO US BIOTECH LTD?

INDO US BIOTECH LTD has a market capitalisation of approximately ₹173 crore.

INDO US BIOTECH LTD

INDOUS·NSE·FMCG

₹87.28▲ +1.58 (+1.84%)

FMCG · Agricultural Products

Revenue under pressure recently

Day₹86.04

₹88.38

52W₹85

₹2062%

Open

₹86.96

High

₹88.38

Low

₹86.04

Prev Close

₹85.70

Volume

4.5K

VWAP

₹87.22

Snapshot

Key fundamentals

Market Cap

₹173 Cr

P/E Ratio

10.76Cheap

P/B Ratio

1.87

EPS

₹8.11

Book Value

₹46.15

ROE

13.15%Average

ROCE

21.00%Efficient

Dividend Yield

0.28%

Debt / Equity

0.40Moderate

Face Value

₹10.00

52W High

₹206.00

52W Low

₹85.01

Sector

FMCG

Industry

Agricultural Products

Expensive

None moatHigh uncertainty

Fair value estimate

₹57

▼ 34.9%downside

Trading at ₹87 — 35% above our estimate

BearFair valueBull

₹47₹57₹92

/100

Business quality — Watch the fundamentals

Growth 0Profitability 58Efficiency 33Valuation 89

Plain English

Our view

Revenue under pressure recently
Low debt relative to equity
Revenue has been shrinking

Strengths

Low debt relative to equity
Capital is working hard (ROCE 21%)
Reasonably priced at 11× earnings
Promoters hold a controlling stake

Risks

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

13% ROE fading to 13% over ~3 yrs, on ₹46 book

₹47

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹92

Analyst target

No analyst coverage

—

Blended fair value₹57

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Capital is working hard (ROCE 21%)
Reasonably priced at 11× earnings
Promoters hold a controlling stake

Bear case

Revenue has been shrinking
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

10.8Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

13.2%Average

Above 15% is considered healthy for Indian equities

ROCE

21.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.40Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹173 Cr

P/B

1.87

EPS

₹8.11

Div Yield

0.28%

What changed

Recent changes

Foreign investors-0.2% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 10.8×

Growth

Strong

+22% rev CAGR

Profitability

Healthy

13.2% ROE

Financial health

Comfortable

D/E 0.40

Momentum

N/A

No technicals

Today

Trading activity

Delivery %69.9%

Turnover₹3.95L Cr

Trades116

VWAP₹87.22

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+21.9%

+23.1%

10Y

+19.2%

Profit

+23.3%

+21.3%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has delivered good profit growth of 20.8% CAGR over last 5 years
Debtor days have improved from 64.6 to 45.5 days.
Company's median sales growth is 20.7% of last 10 years

Watch-outs

Cons

Promoter holding has decreased over last quarter: -1.88%
Tax rate seems low

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors sold 0.17 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

68%

Promoter

Promoters

68.3%0.00

Public

31.7%+0.17

FII / FPI

0.0%-0.17

Quarterly trend

Ownership over time

Q1 FY27

Promoter68.29%

FII0.01%

Public31.70%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2004, Indo US Bio-Tech Ltd is engaged in production and processing of commercial and vegetable seeds[1]